Literature DB >> 30575408

The Association of Biochemical Hypoglycemia with the Subsequent Risk of a Severe Hypoglycemic Event: Analysis of the DCCT Data Set.

Roy W Beck1, Richard M Bergenstal2, Tonya D Riddlesworth1, Craig Kollman1.   

Abstract

OBJECTIVE: To evaluate the association of biochemical hypoglycemia with subsequent severe hypoglycemia (SH) events using the Diabetes Control and Complications Trial (DCCT) data set. RESEARCH DESIGN AND METHODS: The frequency of biochemical hypoglycemia (percentage of values <70 and <54 mg/dL [3.9 and 3.0 mmol/L) was assessed using DCCT blood glucose concentrations measured at a central laboratory from seven finger-stick samples (7-point testing: pre- and 90-min postmeals and at bedtime) collected during 1 day every 3 months. SH events required a change in mental status necessitating the involvement of another individual to provide treatment. A Poisson model accounting for repeated measures from each participant was used to assess the association of biochemical hypoglycemia frequency, computed from the 7-point finger-stick data, with the development of SH events.
RESULTS: The risk of SH during a 3-month period was substantially higher (P < 0.001) when there was at least one hypoglycemic blood glucose value in the preceding 7-point profile, with similar results seen for both the 70 mg/dL (rate ratio = 3.0 [95% confidence interval: 2.6-3.3]) and 54 mg/dL (rate ratio = 2.7 [95% confidence interval: 2.4-3.1]) thresholds.
CONCLUSIONS: The occurrence of biochemical hypoglycemia <70 or <54 mg/dL is associated with an increased risk of SH. For this reason as well as the deleterious effects of hypoglycemia on glucose counter-regulation and hypoglycemia awareness, cognition, quality of life, and arrhythmias, it is important in diabetes management to avoid hypoglycemic glucose levels as much as possible.

Entities:  

Keywords:  Biochemical hypoglycemia; Risk assessment; Severe hypoglycemia; Type 1 diabetes.

Mesh:

Substances:

Year:  2018        PMID: 30575408      PMCID: PMC6909677          DOI: 10.1089/dia.2018.0362

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  39 in total

1.  Episodes of severe hypoglycemia in type 1 diabetes are preceded and followed within 48 hours by measurable disturbances in blood glucose.

Authors:  B P Kovatchev; D J Cox; L S Farhy; M Straume; L Gonder-Frederick; W L Clarke
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

Review 2.  Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2016-11-21       Impact factor: 19.112

3.  Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes.

Authors:  Ruth S Weinstock; Stephanie N DuBose; Richard M Bergenstal; Naomi S Chaytor; Christina Peterson; Beth A Olson; Medha N Munshi; Alysa J S Perrin; Kellee M Miller; Roy W Beck; David R Liljenquist; Grazia Aleppo; John B Buse; Davida Kruger; Anuj Bhargava; Robin S Goland; Rachel C Edelen; Richard E Pratley; Anne L Peters; Henry Rodriguez; Andrew J Ahmann; John-Paul Lock; Satish K Garg; Michael R Rickels; Irl B Hirsch
Journal:  Diabetes Care       Date:  2015-12-17       Impact factor: 19.112

4.  Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes.

Authors:  Ruth E Davis; Malcolm Morrissey; John R Peters; Kim Wittrup-Jensen; Tessa Kennedy-Martin; Craig J Currie
Journal:  Curr Med Res Opin       Date:  2005-09       Impact factor: 2.580

5.  Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus.

Authors:  Setareh A Williams; Michael F Pollack; Marco Dibonaventura
Journal:  Diabetes Res Clin Pract       Date:  2011-01-19       Impact factor: 5.602

6.  The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group.

Authors: 
Journal:  Diabetes       Date:  1986-05       Impact factor: 9.461

7.  Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.

Authors:  Roy W Beck; Richard M Bergenstal; Tonya D Riddlesworth; Craig Kollman; Zhaomian Li; Adam S Brown; Kelly L Close
Journal:  Diabetes Care       Date:  2018-10-23       Impact factor: 19.112

8.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

9.  Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 Diabetes.

Authors:  Peter Novodvorsky; Alan Bernjak; Elaine Chow; Ahmed Iqbal; Lianne Sellors; Scott Williams; Robert A Fawdry; Bhavin Parekh; Richard M Jacques; Jefferson L B Marques; Paul J Sheridan; Simon R Heller
Journal:  Diabetes Care       Date:  2017-02-17       Impact factor: 19.112

10.  Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial.

Authors:  John M Lachin; Ionut Bebu; Richard M Bergenstal; Rodica Pop-Busui; F John Service; Bernard Zinman; David M Nathan
Journal:  Diabetes Care       Date:  2017-04-12       Impact factor: 19.112

View more
  11 in total

1.  Relationship between interstitial glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics; a pilot study.

Authors:  Akemi Tokutsu; Yosuke Okada; Keiichi Torimoto; Yoshiya Tanaka
Journal:  Diabetol Metab Syndr       Date:  2020-08-12       Impact factor: 3.320

2.  Examination of the Igls Criteria for Defining Functional Outcomes of β-cell Replacement Therapy: IPITA Symposium Report.

Authors:  Cyril P Landstra; Axel Andres; Mikael Chetboun; Caterina Conte; Yvonne Kelly; Thierry Berney; Eelco J P de Koning; Lorenzo Piemonti; Peter G Stock; François Pattou; Marie-Christine Vantyghem; Melena D Bellin; Michael R Rickels
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 6.134

3.  Continuous glucose monitoring targets in type 1 diabetes pregnancy: every 5% time in range matters.

Authors:  Helen R Murphy
Journal:  Diabetologia       Date:  2019-06-03       Impact factor: 10.122

4.  Reducing Hypoglycemia in the Real World: A Retrospective Analysis of Predictive Low-Glucose Suspend Technology in an Ambulatory Insulin-Dependent Cohort.

Authors:  Lars Müller; Steph Habif; Scott Leas; Eliah Aronoff-Spencer
Journal:  Diabetes Technol Ther       Date:  2019-08-01       Impact factor: 6.118

5.  Patient-Generated Health Data Integration and Advanced Analytics for Diabetes Management: The AID-GM Platform.

Authors:  Elisa Salvi; Pietro Bosoni; Valentina Tibollo; Lisanne Kruijver; Valeria Calcaterra; Lucia Sacchi; Riccardo Bellazzi; Cristiana Larizza
Journal:  Sensors (Basel)       Date:  2019-12-24       Impact factor: 3.576

Review 6.  Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.

Authors:  Tadej Battelino; Thomas Danne; Richard M Bergenstal; Stephanie A Amiel; Roy Beck; Torben Biester; Emanuele Bosi; Bruce A Buckingham; William T Cefalu; Kelly L Close; Claudio Cobelli; Eyal Dassau; J Hans DeVries; Kim C Donaghue; Klemen Dovc; Francis J Doyle; Satish Garg; George Grunberger; Simon Heller; Lutz Heinemann; Irl B Hirsch; Roman Hovorka; Weiping Jia; Olga Kordonouri; Boris Kovatchev; Aaron Kowalski; Lori Laffel; Brian Levine; Alexander Mayorov; Chantal Mathieu; Helen R Murphy; Revital Nimri; Kirsten Nørgaard; Christopher G Parkin; Eric Renard; David Rodbard; Banshi Saboo; Desmond Schatz; Keaton Stoner; Tatsuiko Urakami; Stuart A Weinzimer; Moshe Phillip
Journal:  Diabetes Care       Date:  2019-06-08       Impact factor: 19.112

7.  Cost Analysis of FreeStyle Libre® 2 System in Type 2 Diabetes Mellitus Population.

Authors:  Itziar Oyagüez; Fernando Gómez-Peralta; Sara Artola; Francisco J Carrasco; Juana Carretero-Gómez; Javier García-Soidan; Ricardo Gómez-Huelgas; Juan F Merino-Torres; Antonio Pérez
Journal:  Diabetes Ther       Date:  2021-05-04       Impact factor: 2.945

8.  Cost analysis of the flash monitoring system (FreeStyle Libre 2) in adults with type 1 diabetes mellitus.

Authors:  Itziar Oyagüez; Juan Francisco Merino-Torres; Miguel Brito; Virginia Bellido; Roque Cardona-Hernandez; Fernando Gomez-Peralta; Francisco Morales-Perez
Journal:  BMJ Open Diabetes Res Care       Date:  2020-07

9.  Effect of real-life insulin pump with predictive low-glucose management use for 3 months: Analysis of the patients treated in a Japanese center.

Authors:  Asako Tsunemi; Junko Sato; Mika Kurita; Yuka Wakabayashi; Naoko Waseda; Mami Koshibu; Mai Shinohara; Atsuko Ozaki; Hiromi Nakamura; Naomi Hirano; Fuki Ikeda; Hiroaki Satoh; Hirotaka Watada
Journal:  J Diabetes Investig       Date:  2020-06-10       Impact factor: 4.232

10.  The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the GOLD randomized trial (GOLD-5).

Authors:  Arndís F Ólafsdóttir; Jan Bolinder; Tim Heise; William Polonsky; Magnus Ekelund; Magnus Wijkman; Aldina Pivodic; Elsa Ahlén; Erik Schwarcz; Thomas Nyström; Jarl Hellman; Irl B Hirsch; Marcus Lind
Journal:  Diabetes Obes Metab       Date:  2020-12-10       Impact factor: 6.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.